20 articles
New research reveals how immune cells use cysteine for both antioxidant defense and energy production, with major implications for cancer treatment.
A 2025 meta-analysis of 11 RCTs finds Tฮฑ1 reduces 28-day sepsis mortality overall, but high-quality trial data tells a more nuanced story.
Systematic uric acid monitoring and treatment achieved 64% better remission rates than waiting for symptoms to guide therapy.
Small NIH study tests oral drug tofacitinib as potential new treatment for systemic lupus erythematosus with fewer side effects.
Natural flavonoid fisetin activates mitophagy and xenophagy pathways to restrict intracellular Salmonella growth in immune cells.
Pfizer's oral JAK inhibitor demonstrated efficacy comparable to adalimumab for treating moderate to severe rheumatoid arthritis.
Scientists identify key mechanism that determines why some immune thrombocytopenia patients maintain remission after stopping treatment.
Revolutionary cell therapy achieves drug-free remission in patients with severe myasthenia gravis, an autoimmune muscle disorder.
A new veterinary sedative is contaminating the illegal fentanyl supply, posing novel overdose risks that standard treatments may not reverse.
Phase 1 trial examines whether vesatolimod can safely stimulate immune response in HIV controllers during treatment interruption.
Daratumumab monotherapy showed promising results in treating refractory lupus nephritis by reducing inflammation and fibrosis.
New research reveals how specialized gut cells maintain protective immunity against parasites, offering insights into immune system optimization.
Combining targeted therapies may help patients with severe hidradenitis suppurativa who don't respond to standard treatments.
Phase I trial tests selective JAK3 inhibitor with improved safety profile compared to existing treatments for inflammatory conditions.
A new in vitro study shows Thymosin ฮฑ1 triggers dendritic cells to release IL-15, boosting CD8+ T cell killing and reducing HIV reservoir size.
Small study tests whether tocilizumab can achieve faster, deeper remission in newly diagnosed rheumatoid arthritis patients.
Pyruvate, a core metabolic molecule, suppresses interferon signaling by directly modifying STAT1 โ linking metabolism to immune control.
A phase 1/2 trial finds low-dose oral NMN safely raises platelet counts in steroid-refractory ITP via a novel immunometabolic mechanism.
Study reveals how inflammation blocks growth hormone production and tests whether etanercept can restore healthy levels in women with RA.
Revolutionary cancer treatment adapted for autoimmune diseases achieves drug-free remission in lupus trials, with RA applications emerging.
